Pro-Gly-Pro tail comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
Regulatory status varies sharply by country. Semax is registered for medical use in Russia, where it appears in formularies as a nasal solution, and it also holds registration in a small number of neighbouring states. It has no approval from the United States Food and Drug Administration or the European Medicines Agency, and it is not a scheduled controlled substance in most jurisdictions. Elsewhere it circulates mainly as laboratory material, so purity documentation comes from suppliers rather than from a national pharmacopoeia.
Semax is a synthetic peptide created in the Soviet Union during the early 1980s by researchers working in Moscow. It was built from the short adrenocorticotropic hormone fragment known as ACTH(4-10), and the chain was then extended with three additional amino acids. The resulting molecule was named semax and entered clinical use in Russia in 1994. It is generally described as a nootropic and neuroprotective agent rather than as a hormone analogue.
Pharmacological accounts link semax to melanocortin signalling and to modulation of neurotrophic factor expression, particularly brain-derived neurotrophic factor and nerve growth factor. Much of this evidence comes from rodent studies using intranasal delivery, a route chosen because it allows peptides to reach the central nervous system with limited systemic exposure. Whether the same mechanisms operate in humans at comparable magnitude remains an open question. The precise receptor or receptors responsible for the reported behavioural and neuroprotective effects have not been conclusively identified.
Clinical reports describe use in ischaemic stroke, transient ischaemic attack, optic nerve conditions, and cognitive complaints, but most of these studies are small and were conducted in a single region. Systematic reviews have generally described the evidence base as limited in size and variable in methodological quality. Randomised controlled data suitable for international regulatory assessment are scarce. As a result, major treatment guidelines outside Russia do not include the peptide, and interest in it remains largely research-driven rather than routine clinical.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic heptapeptide | Analogue of the ACTH(4-10) fragment |
| Amino acid sequence | Met-Glu-His-Phe-Pro-Gly-Pro | Single-letter form MEHFPGP |
| Molecular formula | C37H51N9O10S | Free peptide, nominal mass near 814 Da |
| First registration | 1994, Russia | Nasal formulation for neurological indications |
| Typical purity grade | 95% or higher by HPLC | Research material; higher grades used as reference standards |
The compound was developed during the 1980s at the Institute of Molecular Genetics in Moscow as part of research on fragments of adrenocorticotropic hormone. Early work examined short ACTH-derived sequences that retained neurotrophic effects while lacking the endocrine activity of the full hormone. Semax entered clinical use in Russia during the 1990s, where it received registration for several neurological indications. Outside that region it remained primarily a laboratory research material rather than an approved therapeutic. English-language literature on it grew more slowly and frequently cited the original Russian studies.
Terminology around the compound varies by source. It appears in catalogues and papers as Semax, as the heptapeptide ACTH(4-7)-Pro-Gly-Pro, and under various alphanumeric laboratory codes used by individual suppliers. These names refer to the same sequence but may imply different salt forms, purity grades, or counter-ions. Peptide databases usually list the free base mass, while product descriptions sometimes report acetate or trifluoroacetate salts with a different formula weight. Because naming conventions for research peptides are not standardised across vendors, checking the declared sequence and measured mass is more reliable than relying on a trade name alone.
Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. Its design combines the ACTH(4-7) core fragment with a C-terminal Pro-Gly-Pro extension, a modification intended to improve stability and prolong activity. The molecule is hydrophilic, carries no lipid chains or glycosylation, and has a theoretical mass just over 810 daltons in its free form. All seven residues are proteinogenic amino acids, so no non-natural building blocks appear in the backbone. A free N-terminal methionine and C-terminal proline define the unmodified parent peptide.
Semax is a synthetic heptapeptide whose sequence is Met-Glu-His-Phe-Pro-Gly-Pro. It was developed as a fragment analog of adrenocorticotropic hormone, modeled specifically on the ACTH(4-10) region. The first four residues reproduce that fragment, while a Pro-Gly-Pro tripeptide is appended at the C-terminus. Work on the compound originated in Russia, where it entered clinical use as an intranasal preparation. Its sequence places it among short regulatory peptides studied for effects on the central nervous system rather than on the adrenal axis.
The C-terminal Pro-Gly-Pro extension is not incidental. Proline-rich tails are known to resist several common peptidases, and the published literature attributes the longer half-life of Semax, relative to unmodified ACTH fragments, to this feature. The modification also removes the melanocyte-stimulating and corticosteroidogenic activity that characterizes longer ACTH-derived sequences. Because the molecule is small and hydrophilic, it is typically formulated as an aqueous solution for intranasal or parenteral delivery. Acetylation or amidation at the termini appears in closely related research peptides and shifts the mass by a fixed increment.
Russian regulatory authorities approved the peptide for nasal administration, and it remains listed in the national pharmacopoeia under several trade names. Documented indications include acute ischemic stroke, transient ischemic attacks, traumatic brain injury, and certain ophthalmological and neurological conditions. Physicians also prescribe it for cognitive complaints in older patients, although the evidence base for that use is thinner. Outside Russia and a few neighboring states, the substance is not an approved medicine and is sold instead as a research chemical.
Later generations of the molecule include an N-acetylated form and an amidated form, both marketed online alongside the parent peptide. These variants differ in terminal chemistry and stability, and they are frequently discussed in the same breath even though they have not been compared in controlled trials. Supply outside formal healthcare systems comes largely from laboratories that synthesize peptides to order. Purity and identity of these materials vary widely, and no single body oversees the international trade.
Semax is a synthetic heptapeptide developed in the Soviet Union during the 1980s by researchers at the Institute of Molecular Genetics in Moscow. It was designed as a truncated analog of adrenocorticotropic hormone, retaining only the fragment spanning residues four through ten. Investigators sought a peptide that would preserve the cognitive effects associated with ACTH while eliminating the hormonal stimulation of the adrenal cortex. The compound entered clinical use in Russia during the following decade.
Semax is a synthetic heptapeptide whose sequence is Met-Glu-His-Phe-Pro-Gly-Pro. The first four residues correspond to the ACTH(4-10) fragment, while the terminal Pro-Gly-Pro extension was added to improve metabolic stability. Its molecular formula is C37H51N9O10S and its monoisotopic mass is approximately 813.9 Da. The compound is classified as a peptide research chemical and as a registered pharmaceutical product in Russia, but it does not hold marketing approval in the European Union or the United States. Naming conventions vary across supplier catalogs.
Development of the compound took place in the Soviet Union during the 1980s, largely through peptide research groups affiliated with the Shemyakin-Ovchinnikov Institute and Moscow State University. Investigators screened fragments of adrenocorticotropic hormone for activity on the central nervous system while attempting to separate cognitive effects from hormonal ones. The shortened sequence was selected because it retained behavioral activity in animal models without stimulating corticosteroid release. Early publications described the molecule as an ACTH(4-10) analog.
Published research on this peptide originates mainly from Russian laboratories, and the wider international literature is comparatively thin. Studies have used rodent models of stroke, hypoxia, and memory tasks, with a smaller number of human trials reported. Reported outcomes include changes in attention and memory measures, along with effects on neurotrophic factor expression in some experiments. Small sample sizes, inconsistent dosing protocols, and limited independent replication are widely noted limitations, so the strength of the clinical evidence remains an open question.
=== Skin cancers === MCH has been identified in both melanoma and squamous cell carcinoma cell lines. However, pro-MCH, a precursor to MCH, has not been found in melanocytes, keratinocytes, or fibroblasts, which might indicate MCH might be brought into these cells by macrophages as part of the immune response. More research is needed to fully determine and understand any relationship between MCH and possible immune responses in skin.
== Pharmaceutical and legal impact == In the United States, the first company to develop a drug ("pioneer") must demonstrate that the drug is safe and effective by extensive and expensive trials. After that, there would be a period of exclusive rights to sell the drug, after which other companies ("generics") can market the same drug as a generic chemical under the Abbreviated New Drug Application. The pioneer companies often attempt to evergreen the patent drug by many methods. Since the appearance of generics can decrease the revenue rate of patented drugs by as much as 80%, this is very profitable. When disappearing polymorphs are involved, it is sometimes true that the pioneer company first discovered and patented polymorph A, then polymorph B, but polymorph A inevitably converts to polymorph B when seeded with microscopic amounts of B. This then means that later companies, even if they follow all the steps specified by the pioneering patent, end up with a polymorph B. Since with disappearing polymorphism, it is practically impossible for anyone to produce the original drug without it turning into the new one, producers are effectively barred from selling generics until the patent for the new polymorph has run out. Alternatively, they may try to argue that a new polymorph needs to undergo the same trials as new drugs, potentially delaying release of a generic for years.
Ni + 4 CO → Ni(CO)4 (1 bar, 55 °C) Fe + 5 CO → Fe(CO)5 (100 bar, 175 °C) Nickel tetracarbonyl is formed with carbon monoxide already at 80 °C and atmospheric pressure, finely divided iron reacts at temperatures between 150 and 200 °C and a carbon monoxide pressure of 50–200 bar. Other metal carbonyls are prepared by less direct methods.
Many firms, like Parcelforce, FedEx and R+L Carriers transport various types of cargo by road, including letters, houses, and cargo containers. Food is commonly transported on roads in order to regularly supply supermarkets with fresh food. Retailers and manufacturers of all kinds use delivery trucks, ranging in size from full semi trucks to smaller delivery vans. Organizations such as the World Bank sometimes use the level of commercial freight transported by smaller businesses as a barometer of healthy economic development.
August 15, 2009: Argentina Even though official government sources state that Argentina's GDP will actually grow this year (and have only recognized a GDP shrinking in June of 0.4% and in July, of 0.3%; both compared to last year's same months), private consulting firms state that Argentine economy has actually been in recession since October 2008. According to them, Argentine GDP shrank 2.9% in the last quarter of 2008, 1.6% in the first quarter of 2009, and 0.6% in the second one. It's widely known in Argentina that the official statistics office in charge of producing this information, INDEC, is not very reliable for trustworthy statistical information, due to the government's mismanagement of the office.
Sources: en.wikipedia.org
==== Goat silk as milk byproduct ==== Researchers at the University of Wyoming have devised a method to introduce spider silk-spinning genes into goats, enabling the extraction of silk protein from the goats' milk. This innovation has applications in various fields, including medicine, where the strength and elasticity of spider silk has been argued to be utilized in artificial ligaments, tendons, eye sutures, and jaw repair. Traditionally, obtaining spider silk in sufficient quantities necessitates managing large populations of spiders, which often leads to territorial conflicts and cannibalism within the farmed spider population. To circumvent this challenge, scientists have genetically engineered goats to produce the silk protein exclusively in their milk. Through selective breeding, a percentage of the offspring inherit the silk protein gene, leading to higher yields of the silk protein. The transgenic goats exhibit no discernible differences in health, appearance, or behavior compared to non-transgenic counterparts. In the future, the researchers aim to transfer silk genes into alfalfa plants, a move the researchers expect to further increase silk production. Researchers believe that alfalfa's widespread distribution and high protein content make it a promising candidate for large-scale silk protein synthesis.
== Recent developments == In 2025, media reports indicated continued competition over milk quotas, with some agricultural colleges losing supplier rights under revised regulations. Later the same year, the Cabinet of Thailand approved an additional 800 million baht in emergency funds to address issues of stockpiled UHT milk and delayed deliveries.
== Use == The juice is drinkable, yet not palatable in its pure form due to its bitter taste. The bitterness diminishes as the hemp juice is mixed with fruit or vegetable juices. The hemp juice simultaneously heightens the fruity, savory and sweet taste of juices and foods in general. Therefore hemp juice is often used in drinks, certain food dishes, seasoning, food supplements, medical products as well as cosmetics. The press remnants can also be used as food supplements.
There is no known specific preventive measure for type 1 diabetes. However, islet autoimmunity and multiple antibodies can be a strong predictor of the onset of type 1 diabetes. Type 2 diabetes—which accounts for 85–90% of all cases worldwide—can often be prevented or delayed by maintaining a normal body weight, engaging in physical activity, and eating a healthy diet. Higher levels of physical activity (more than 90 minutes per day) reduce the risk of diabetes by 28%. Dietary changes known to be effective in helping to prevent diabetes include maintaining a diet rich in whole grains and fiber, and choosing good fats, such as the polyunsaturated fats found in nuts, vegetable oils, and fish. Limiting sugary beverages and eating less red meat and other sources of saturated fat can also help prevent diabetes. Tobacco smoking is also associated with an increased risk of diabetes and its complications, so smoking cessation can be an important preventive measure as well. The relationship between type 2 diabetes and the main modifiable risk factors (excess weight, unhealthy diet, physical inactivity and tobacco use) is similar in all regions of the world. There is growing evidence that the underlying determinants of diabetes are a reflection of the major forces driving social, economic and cultural change: globalization, urbanization, population aging, and the general health policy environment.
Sources: en.wikipedia.org
Alfred Russel Wallace's 1879 book Australasia, Ian Todd's 1974 book Island Realm: A Pacific Panorama and Dean Kohlhoff's 2002 book Amchitka and the Bomb: Nuclear Testing in Alaska all associate the Aleutian Islands with the Oceania region due to their status as remote islands in the Pacific. The islands, having biogeographical and ethnocultural affinities to North America, are not ordinarily considered a part of the region.
== Discovery == The N-acetylmuramoyl-L-alanine amidase enzymatic activity was first observed in human and mouse serum in 1981 by Branko Ladešić and coworkers. The enzyme (abbreviated NAMLAA) was then purified from human serum by this and other groups. The sequence of 15 N-terminal amino acids of NAMLAA was identified, but the cDNA for the protein was not cloned and the gene encoding NAMLAA was not known. In 2000, Dan Hultmark and coworkers discovered a family of 12 Peptidoglycan Recognition Protein (PGRP) genes in Drosophila melanogaster and by homology searches of available human and mouse sequences predicted the presence of long forms of human and mouse PGRPs, which they named PGRP-L by analogy to long forms of insect PGRPs. In 2001, Roman Dziarski and coworkers discovered and cloned three human PGRPs, named PGRP-L, PGRP-Iα, and PGRP-Iβ (for long and intermediate size transcripts), and established that human genome codes for a family of 4 PGRPs: PGRP-S (short PGRP) and PGRP-L, PGRP-Iα, and PGRP-Iβ. Subsequently, the Human Genome Organization Gene Nomenclature Committee changed the gene symbols of PGRP-S, PGRP-L, PGRP-Iα, and PGRP-Iβ to PGLYRP1 (peptidoglycan recognition protein 1), PGLYRP2 (peptidoglycan recognition protein 2), PGLYRP3 (peptidoglycan recognition protein 3), and PGLYRP4 (peptidoglycan recognition protein 4), respectively, and this nomenclature is currently also used for other mammalian PGRPs. Sergei Kiselev and coworkers also independently cloned mouse PGLYRP2 (which they named TagL).
gas chromatography A type of chromatography commonly used in analytical chemistry to isolate and analyze chemical compounds that can be vaporized without decomposition. Gas chromatography is often used to test the purity of substances, to identify unknown substances, and to measure the relative amounts of the different components of mixtures.
Sources: en.wikipedia.org
Registered medical products are most often 0.1% nasal drops. Research suppliers ship lyophilized powder, usually in milligram quantities, which is dissolved before use. The active peptide is the same in both cases; presentation and excipients differ.
No. The peptide is synthetic, although it is modelled on a fragment of a naturally occurring hormone. ACTH(4-10) is generated when ACTH is cleaved, but the Pro-Gly-Pro extension is not a known endogenous sequence. It is therefore a designed analogue rather than a natural metabolite.
The label reflects reported effects on attention, memory and recovery after neurological injury in regional clinical reports. Those reports are mostly small and have not been widely replicated outside the region. The classification is descriptive and does not imply a single defined mechanism.
It is described as a synthetic analogue of the ACTH(4–10) fragment, a short segment of adrenocorticotropic hormone. Its sequence differs from that fragment and includes two proline residues, which influence stability and behaviour in solution.